$GILD Company News 10 stocks loved by advisers who beat

New Post Public Reply Private Reply Replies (0) Message Board

Oct 21, 2014 at 12:30 PM

$GILD Company News

10 stocks loved by advisers who beat bear markets 7:35 p.m. Oct. 15, 2014 - Mark Hulbert
NYSE to expand number of companies on biotech index 5:52 p.m. Oct. 14, 2014 - Wallace Witkowski
J&J's earnings jump on higher drug sales 8:12 a.m. Oct. 14, 2014 - MarketWatch.com
Gilead’s new drug is even pricier than Sovaldi 5:29 p.m. Oct. 10, 2014 - Russ Britt
The most profitable companies get the best stock returns 8:31 a.m. Oct. 10, 2014 - Philip van Doorn
Bristol-Myers drops Hepatitis C dual regimen in U.S. 11:15 a.m. Oct. 7, 2014 - Jonathan D. Rockoff
Mylan boosts full-year outlook on product launches 8:11 a.m. Oct. 3, 2014 - MarketWatch.com
During times like these, cash is king 2:03 p.m. Oct. 2, 2014 - The Trading Deck
Sovaldi pricing raises debate over drug costs 2:57 p.m. Oct. 1, 2014 - Jani Actman of Medill News Service
It’s crucial to watch growth stocks right now 3:06 p.m. Sept. 25, 2014 - The Trading Deck
Gilead Sciences shares up 1.5% 9:39 a.m. Sept. 25, 2014 - Sue Chang
14 stocks loved by top-performing fund managers 6:49 a.m. Sept. 18, 2014 - Philip van Doorn
Market pullbacks present promise, not peril 1:58 p.m. Sept. 16, 2014 - The Trading Deck
Gilead Sciences shares slide 2.6% 9:39 a.m. Sept. 15, 2014 - Sue Chang
Two tech stocks with big potential 2:14 p.m. Sept. 11, 2014 - The Trading Deck
Why Apple exemplifies everything that’s wrong with Silicon Valley 12:51 p.m. Sept. 9, 2014 - Tim Mullaney
There’s good news for speculative growth traders 2:39 p.m. Sept. 2, 2014 - The Trading Deck
Trade what you see, not what you believe 2:48 p.m. Aug. 29, 2014 - The Trading Deck
Don’t read too much into this week’s action 2:01 p.m. Aug. 26, 2014 - The Trading Deck
Gilead Sciences shares rise 2.5% to pace S&P 500 gainers 9:34 a.m. Aug. 25, 2014 - Tomi Kilgore

BI begins enrollment in Phase 3 CRC trial 9:08 a.m. Today - Seeking Alpha
Gilead Sciences: Clear The Dockets And Settle With Merck Already 9:07 a.m. Today - Seeking Alpha
Alexion: Keeping Up The Suspense Ahead Of Q3 Earnings 5:01 p.m. Oct. 20, 2014 - Investors Business Daily
3 Drugs Stocks Pushing Industry Growth 1:17 p.m. Oct. 20, 2014 - TheStreet.com
Stocks Slide on Indiscriminate Selling 10:40 a.m. Oct. 20, 2014 - Barrons.com
LabCorp launches new HIV test 10:40 a.m. Oct. 20, 2014 - Seeking Alpha
Gilead: Stage Set For Rally 8:27 a.m. Oct. 20, 2014 - Seeking Alpha
End Of The Year Events To Drive Some Of October's Beaten Up Biotech Companies 7:40 a.m. Oct. 20, 2014 - Seeking Alpha
Cramer's Lightning Round - Ensco Is One Of The Worst Stocks I've Owned In My Life (10/17/14) 6:24 a.m. Oct. 19, 2014 - Seeking Alpha
'Mad Money' Lightning Round: Lots of Ways to Win With Molson Coors 6:00 a.m. Oct. 18, 2014 - TheStreet.com
Jim Cramer's 'Mad Money' Recap: Here's Next Week's Game Plan 8:16 p.m. Oct. 17, 2014 - TheStreet.com
Gilead's Harvoni Receives Notice of Compliance from Canada - Analyst Blog 4:30 p.m. Oct. 17, 2014 - Zacks.com
A Harvoni Vs. Olysio Price War Will Be Nonexistent: Consider Buying Gilead Now 1:54 p.m. Oct. 17, 2014 - Seeking Alpha
Health Canada issues notice of compliance for Gilead's Harvoni(TM) (ledipasvir/sofosbuvir), the first once-daily single tablet regimen for the treatment of genotype 1 chronic hepatitis C 2:44 p.m. Oct. 16, 2014 - CNW Group
2 Companies That Don't Deserve This Market Beatdown 8:14 a.m. Oct. 16, 2014 - Seeking Alpha
Novavax Begins Mid-Stage Study on RSV Vaccine in Elders - Analyst Blog 5:20 p.m. Oct. 15, 2014 - Zacks.com
Best U.S. Stock Ideas Today 3:57 p.m. Oct. 15, 2014 - Seeking Alpha
Barclays: Johnson & Johnson's Q3 Could Be 'High Water Mark' 3:42 p.m. Oct. 15, 2014 - benzinga.com
Biotech Stock Roundup: Gilead Nabs FDA Nod for Combo HCV Drug, Auxilium Accepts Endo Offer - Analyst Blog 1:59 p.m. Oct. 15, 2014 - Zacks.com
Healthcare ETFs in Focus on JNJ Earnings Beat - ETF News And Commentary 1:00 p.m. Oct. 15, 2014 - Zacks.com

Acquisition Updates, Drug Approval, Drug Development Discontinuation, and Contract Update - Research Reports on AbbVie, Gilead, Pfizer, Lilly and Aetna 8:35 a.m. Oct. 20, 2014 - PR Newswire - PRF
Health Canada Issues Notice of Compliance for Gilead’s Harvoni™ (Ledipasvir/Sofosbuvir), the First Once-Daily Single Tablet Regimen for the Treatment of Genotype 1 Chronic Hepatitis C 1:30 p.m. Oct. 16, 2014 - BusinessWire - BZX
Critical Alerts For Tesla Motors, Tekmira Pharmaceuticals, Gilead Sciences, 3D Systems and TASER International Released By InvestorsObserver 9:31 a.m. Oct. 15, 2014 - PR Newswire - PRF
Pre-market Biotech Picks - Gilead Sciences, MannKind, IsoRay, Orexigen Therapeutics, and Sunesis Pharma 9:00 a.m. Oct. 14, 2014 - PR Newswire - PRF
U.S. Food and Drug Administration Approves Gilead’s Harvoni® (Ledipasvir/Sofosbuvir), the First Once-Daily Single Tablet Regimen for the Treatment of Genotype 1 Chronic Hepatitis C 1:54 p.m. Oct. 10, 2014 - BusinessWire - BZX
Marketing Application Update, Acquisitions, Collaborations, FDA Approvals, and Structural Changes - Research Reports on Gilead, BD, Pfizer, AbbVie and Novartis 8:55 a.m. Oct. 10, 2014 - PR Newswire - PRF
Positive Study Results, Acquisitions, Drug Approval, Regulatory Updates, and Collaborations - Research Reports on Gilead, Pfizer, AbbVie, Pacira and Thermo Fisher 8:50 a.m. Sept. 30, 2014 - PR Newswire - PRF
European CHMP Adopts Positive Opinion for Gilead’s Harvoni® (Ledipasvir/Sofosbuvir) for the Treatment of Chronic Hepatitis C Infection in Adults 7:18 a.m. Sept. 26, 2014 - BusinessWire - BZX
Critical Alerts For Gilead Sciences, Ambarella, American Capital Agency, NetApp and Ford Released By InvestorsObserver 10:33 a.m. Sept. 24, 2014 - PR Newswire - PRF
Critical Alerts For Gilead Sciences, Ambarella, American Capital Agency, NetApp and Ford Released By InvestorsObserver 9:37 a.m. Sept. 24, 2014 - PR Newswire - PRF
Gilead’s Investigational Tenofovir Alafenamide (TAF)-Based Single Tablet HIV Regimen Meets 48-Week Primary Objective in Two Phase 3 Studies 8:30 a.m. Sept. 24, 2014 - BusinessWire - BZX
Gilead Submits New Drug Application to Japan’s Pharmaceutical and Medical Devices Agency for Fixed-Dose Combination of Ledipasvir/Sofosbuvir for Chronic Hepatitis C Genotype 1 Infection 12:00 a.m. Sept. 24, 2014 - BusinessWire - BZX
Licensing Agreements, Results of Clinical Trials, and Acquisitions - Research Reports on Gilead, AbbVie, Pfizer, Auxilium and Endo 9:05 a.m. Sept. 22, 2014 - PR Newswire - PRF
Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 8:15 a.m. Sept. 19, 2014 - PR Newswire - PRF
European Commission Grants Marketing Authorization for Gilead’s Zydelig® (Idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma 6:23 a.m. Sept. 19, 2014 - BusinessWire - BZX
Gilead Announces Data From Phase 2 Study of Simtuzumab for Previously Untreated Pancreatic Cancer 6:00 a.m. Sept. 17, 2014 - BusinessWire - BZX
AHF Joins National Coalition on Health Care’s ‘Campaign for Sustainable Rx Pricing’ 6:21 p.m. Sept. 16, 2014 - BusinessWire - BZX
Hetero Enters License Agreement With Gilead Sciences Inc., USA to Produce Generic Sofosbuvir for Treatment of Chronic Hepatitis C 5:50 p.m. Sept. 16, 2014 - Marketwire
Gilead Announces Generic Licensing Agreements to Increase Access to Hepatitis C Treatments in Developing Countries 6:30 a.m. Sept. 15, 2014 - BusinessWire - BZX
Mylan Signs Agreement with Gilead to Accelerate Access to Hepatitis C Treatments, Sovaldi® (Sofosbuvir) and Single Tablet Regimen of Ledipasvir/Sofosbuvir, in Developing Countries 6:30 a.m. Sept. 15, 2014 - PR Newswire - PRF

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sarepta Under Scrutiny: KSF's Investigation Deepens

A Troubling Chapter for Sarepta Therapeutics It's not every day that a company's dirty laundry gets hung out for all to see, especially when we're talking about Sarepta Therapeutics, a player in the rare disease treatment space. But that's exactly where we find ourselves this fine day—a bit like kicking a hornet's nest, if you ask me. Led by the former Louisiana...

Cyngn: A Deep Dive into Its Robust 24-Patent Portfolio

Cyngn's Growing Patent Portfolio: A Robust Defense Ah, Cyngn Inc., the hotshot in AI-powered autonomous vehicle tech, is flexing its muscles with a solid 24-patent stash. We're talking about a company that's not messing around, racking these up since they decided to dive head-first into solving the brain-busting problems of the industrial sector. Their strategy? Build and...

New Concierge Pediatric Care at Weill Cornell Launches

A New Way Forward in Pediatric Care When a couple of seasoned pediatricians decide it's time for something fresh, eyes and ears perk up. Enter Dr. Paul W. Chung and Dr. Jane E. Rosini, diving headfirst into a revolutionary pediatric concierge program courtesy of Concierge Choice Physicians (CCP). We're talking a substantial shake-up at Weill Cornell Medicine, aiming to...

Postal Service Defends New Rule Amid Speculation

USPS Navigates Election Mail Controversies The U.S. Postal Service has found itself in the eye of a political storm, thanks to the latest Federal Ballot Mail Rule. Led by Postmaster General David Steiner, the USPS is setting the record straight amidst swirling misinformation and skepticism about its recent actions. This is not just a postal service under scrutiny—it's a...

Acepodia's ACE723 Clears FDA Hurdle for Hepatocellular Push

Unexpected Developments from Acepodia Folks keeping a keen eye on the biotech scene might just raise an eyebrow at Acepodia's latest move. The FDA has given their nod to ACE723, an ambitious dual-payload antibody-drug conjugate (ADC) designed to wrangle with those stubborn cases of unresectable or metastatic hepatocellular carcinoma (HCC). This isn't just another day in...

BellRing Brands Faces Legal Probe; Fiduciary Duties Questioned

What's Stirring at BellRing Brands? Hey, no time like the present to dive headfirst into this mess BellRing's found itself in. On the heels of a lackluster sales forecast, just announced about a year ago, Kahn Swick & Foti's got their magnifying glasses out, searching for any shady dealings by those running the show at BellRing Brands, LLC. Why Is BellRing in the Hot...

S&P 500 Shuffle: Bloom, Illumina, Everpure Join Frenzy

Index Shuffles Stir Market Pot Changes are afoot, folks, with the movers and shakers of the market indices stepping into the spotlight. A lot is brewing with S&P Dow Jones Indices making significant switches effective September 21, 2026—right before trading heats up. You better believe it's affecting more than a couple of tickers. Who's In and Who's Out? If you’ve...

TrailBlazer Magazine Snags a Tribune for In-House Design

Who Knew? Design Awards Aren't Just for Pretty Pictures TrailBlazer Magazine gets a pat on the back from GDUSA's 2026 Inhouse Design Awards, a nod to top-notch design work. With over 4,000 entries across the board, getting into the top 10 percent is like finding a steakhouse with zero line on a Friday night. Not exactly common, right? Design Worth Cheering For The winning...

MMRO Achieves URAC AI Accreditation, Ensures Compliance

A Milestone in Healthcare AI: MMRO's New Accreditation When AI in healthcare gets an official nod from the big guys like URAC, it's a significant moment. We're talking about Managed Medical Review Organization, Inc. (MMRO), a firm that's just earned the URAC Artificial Intelligence in Health Care Accreditation. Now, this isn't just some rubber stamp; it's a testament to...

Dimerix Locks Down A$34M Loan: No Shareholder Dilution

Dimerix Grabs Non-Dilutive Funds amid Kidney Trials Here we go with Dimerix's latest move, folks. They roped in A$34 million through a cozy get-together with lenders from Australia and the U.S. What's the kicker? This cash won't touch shareholder equity. So, breathe easy, investors. It's a rare feat to pull off non-dilutive funds these days, especially in the biopharma...